Asthma Clinical Research Network (ACRN)

This study will establish a network of interactive asthma clinical research groups to evaluate current therapies, new therapies, and management strategies for adult asthma.

BACKGROUND:

Asthma is an increasingly serious cause of morbidity and mortality in the United States. There are approximately 12 million asthmatics, and the disease affects both sexes and impacts all racial and ethnic groups. It is now recognized that asthma is a complex disease of varied etiology, which is triggered by a number of factors (e.g., allergens, drugs, chemicals, exercise, cold air, infections, and emotions), making asthma therapy difficult and sometimes complicated. Multiple drugs, including medications to treat and control symptoms (bronchodilator agents such as beta-adrenergic agonists, theophylline, and anticholinergics) and medications thought to control underlying airway inflammation (e.g., inhaled and systemic corticosteroids, cromolyn sodium, and nedocromil), are often required.

Despite major advances in the understanding of the etiology and pathophysiology of asthma and the development of new therapeutic modalities, the prevalence, severity, and mortality from asthma in all age groups have increased over the past decade. Mortality rates are disproportionately high in urban and rural minority populations. Hospitalizations for asthma have doubled in adults and increased five-fold for children over the past 20 years. Asthma continues to place a heavy burden on patients and their families, the health care system, and society as a whole. Therefore, new approaches are needed to help alleviate this growing problem.

A particularly important need at this juncture is a mechanism for the rapid evaluation of new and existing therapeutic approaches for asthma and for the dissemination of laboratory and clinical findings to the health care community. The Asthma Clinical Research Network (ACRN) program seeks to accomplish this through the development of a network of interactive asthma clinical groups that conduct clinical studies employing common protocols in a coordinated and multidisciplinary setting. This will ensure ready access to an adequate number of well characterized patients from diverse populations and age groups. It will also bring together and coordinate the necessary clinical expertise and administrative resources to conduct multiple therapeutic studies. Centralized protocols will promote high quality design, decrease the variability in supportive modalities, and reduce the redundant utilization of resources required for rapidly conducting multiple independent clinical studies. The separate data coordinating center supports protocol and questionnaire development, sample size calculations, complete data analysis, and overall study coordination.

The initiative was developed by the Pulmonary Diseases Advisory Committee working group, approved by the full committee at the February 1992 meeting, and given concept clearance by the National Heart, Lung, and Blood Institute (NHLBI) Advisory Council in May 1992.

DESIGN NARRATIVE:

The Beta-Agonist (Bags) study compared the safety and efficacy of regular plus "as needed" use of inhaled albuterol to the "as needed" use of inhaled albuterol in 255 patients with asthma of mild severity. A total of 230 patients completed the study. The study was randomized, double-blind, and placebo-controlled with parallel groups. Following a 6-week single-blind run-in period, patients were randomized in a double-blind manner and treated for 16 weeks. There was a 4-week withdrawal, or run-out, period. Changes in lung function and asthma symptoms were assessed to determine whether regular or "as needed" beta-agonist use was more beneficial in the treatment of mild asthma. Specific outcome measures included morning (AM) PEF, airway responsiveness, spirometric values, evening (PM) to AM PEF difference index, asthma symptoms, quality of life measures, use of rescue medications, and episodes of adverse asthma control. Recruitment began in December 1994. The study has completed and results have been published.

The Colchicine in Moderate Asthma (CIMA) study examined if colchicine offered therapeutic benefit in the management of 71 patients with moderate asthma when corticosteroids were discontinued. The study was randomized, double-blind, and placebo-controlled with two parallel groups. A 2-week run-in with inhaled corticosteroid was followed by 2 weeks with inhaled corticosteroid and colchicine or placebo, and then by 6 weeks with no inhaled corticosteroid but with colchicine or placebo. There was a 6-week single-blind run-out. Outcome measures included treatment failure after cessation of inhaled corticosteroid, FEV1 change, PM to AM PEF difference index, airway responsiveness, asthma symptoms, quality of life measures, use of rescue medications, and episodes of adverse asthma control. The protocol was approved in April 1994. Recruitment ran from February 1996 through August 1996. Results have been published.

The Salmeterol or Corticosteroids (SOCS) study was a randomized, double-blind study to determine the utility of treating patients with moderately severe asthma with long-acting beta-agonists in place of inhaled corticosteroids (ICS). A total of 164 patients were randomized into one of the following three treatment arms (double-blind and double-dummy): 1) placebo; 2) inhaled corticosteroid triamcinolone alone; or 3) beta-agonist salmeterol alone. Treatment continued for 16 weeks, followed by a 6-week run-out period in which all patients were placed on placebo. The purpose of the run-out period was to evaluate the effects of treatment cessation on asthma control. To compare efficacy of therapy, the primary outcome variable was the change in AM PEF from the final week of the run-in period to the final week of the double-blind treatment period. To compare duration benefit, the primary outcome variable was again AM PEF, with a comparison of the change from the final week of the run-in period to the second and final weeks of the run-out period. Secondary endpoints included other markers of asthma severity (e.g., FEV1, symptom diaries, beta-agonist rescue, quality-of-life scores, methacholine responsiveness, and asthma exacerbations). To evaluate markers of inflammation, sputum induction was performed on all patients, and bronchoalveolar lavage and bronchial biopsy were performed on a subset of patients. Enrollment began in February 1997 and ended in July 1998. Results have been published.

The Salmeterol± Corticosteroids (SLIC) study examined the addition of a long acting beta-agonist, salmeterol, on a scheduled basis for patients with moderate asthma whose symptoms were sub-optimally controlled by using an inhaled beta-agonist on an "as needed" basis and an inhaled corticosteroid on a scheduled basis. The study determined if the addition of salmeterol on a scheduled basis permitted a reduction in dose, and/or elimination of inhaled corticosteroids over time, without a concomitant increase in asthmatic symptoms or a decrease in the bronchoprotective effect to aerosolized methacholine. Recruitment of randomized patients with moderate asthma began in January 1997. Additional patients were randomized at the Harlem Center, a center added to the network in December 1995. The enrollment of 175 patients ended in July 1998 and the last patient visits were completed in January 1999. Results have been published.

The Dose of Inhaled Corticosteroids with Equisystemic Effects (DICE) study estimated dose-response curves with respect to adrenal suppression for six distinct inhaled corticosteroids. The inhaled steroids and delivery systems were characterized in terms of systemic effects so that doses that produced "equi-systemic" effects could be subsequently compared in future efficacy studies, including the efficacy study "Measuring Inhaled Corticosteroid Efficacy" (MICE). In DICE, a total of 156 (58% male and 31% minority) patients with mild to moderate asthma had a baseline visit and a placebo run-in period to practice taking scheduled doses (4 puffs twice a day) from a metered dose inhaler for 1 week. At the second visit, patients were randomized to placebo or to one of the following six steroid arms, including: 1) beclomethasone dipropionate metered dose inhaler (MDI); 2) budesonide dry powder; 3) flunisolide MDI; 4) fluticasone propionate MDI; 5) fluticasone propionate dry powder; or 6) triamcinolone acetonide MDI. The study addressed the following questions: 1) Were there dose-response relationships in the suppression of overnight plasma cortisol with the various inhaled corticosteroids and delivery systems?; 2) If the dose-response relationships existed, at which doses were comparable systemic effects evident as determined by suppression of overnight plasma cortisol?; and 3) If dose-response relationships existed, which dose produced a 10%, 20%, 30%, or 40% suppression of adrenal steroid secretion (cortisol) for each inhaled steroid and delivery system? DICE was initiated in September 1998 and completed in November 1999. Results have been published.

The Measuring Inhaled Corticosteroid Efficacy (MICE) pilot study was approved by the Protocol Review Committee in August 1998. MICE used doses of inhaled corticosteroid for the full MICE protocol as derived from DICE, which induced minimal cortisol suppression (highest deliverable dose that caused less than 5% cortisol suppression), 20% to 30% cortisol suppression, and 40% to 60% cortisol suppression. The intent was to determine if different inhaled corticosteroids, which had equisystemic effects, had differential salutary therapeutic effects in chronic asthma, or if therapeutic efficacy paralleled systemic effects. MICE was a 24-week, randomized, open-label, prospective, multi-center study examining the effect of inhaled beclomethasone dipropionate (BDP) and fluticasone propionate (FP) both with an Opti-Chamber spacer device. The inhaled corticosteroids were administered to 30 patients in doses of increasing systemic effect to examine the corresponding effects on pulmonary function, bronchial hyper-responsiveness, asthma control, and resolution of airway inflammation in patients with persistent asthma. The intent was to compare the estimates of systemic effect for BDP and FP, derived from the DICE pilot study in which BDP and FP were administered in 1-week intervals, to that which occurred when BDP and FP doses were administered over 3- to 6-six week intervals with incremental doses. MICE also explored which efficacy/systemic relationships, if any, suggested that there may be a difference between the two prototype inhaled corticosteroids, BDP and FP. Recruitment was completed in the spring of 2000. Results have been published.

The Beta Agonist Response by Genotype (BARGE) study was reviewed by the Protocol Review Committee in December 1998. Recruitment started in September 1999. BARGE was a 54-week randomized, double-blind, crossover study comparing the effects of regularly scheduled use of inhaled albuterol (2 puffs four times a day) to placebo. Two groups of 36 participants each included individuals who had mild to moderate asthma and who differed by their genotype at the codon for the 16th amino acid of the B2-adrenergic receptor. A total of 36 participants harbored the B16-Arg/Arg genotype and the other 36 harbored the B16-Gly/Gly genotype at the B2-adrenergic receptor. Qualified participants entered a 6-week single-blind run-in period during which they were treated with an inhaled placebo (2 puffs 4 times a day) and given inhaled ipratropium bromide for use as a rescue medication. Asthma control was characterized by AM PEF, spirometric values, AM/PM PEF variability index, asthma symptoms, quality of life, use of rescue medications, and occurrence of events of adverse asthma control. Baseline data were obtained on airway responsiveness, the protective effect of albuterol against methacholine-induced bronchoconstriction, the maximum bronchodilator effect of albuterol, and exhaled nitric oxide. Participants were then randomized to a 16-week double-blind treatment phase in which they received either inhaled albuterol or placebo (two puffs 4 times a day). Asthma control was monitored by the above indicators during this time. At the end of the blinded treatment period, all participants were returned to single-blind regular use of a placebo inhaler (2 puffs 4 times a day) for an 8-week run-out period. Following cross-over to double-blinded treatment with albuterol or placebo, the 8-week run-out period also served as the run-in period for the second stage of the study. Asthma control was monitored by the same indicators as in the first stage. At the end of the second blinded treatment period, all participants were returned to single-blind regular use of a placebo inhaler (2 puffs 4 times a day) for an 8-week run-out period. During the entire study, participants used inhaled ipratropium bromide as rescue medication to avoid the confounding effects of B2-adrenergic stimulation on the outcome variables to be monitored. In the event that an episode of adverse asthma control responded incompletely to ipratropium, albuterol was used as a superseding rescue medication. Comparisons of asthma control, within each genotypic group during periods of randomized treatment, were assessed as the difference in the change in outcome variables between the end of Stage 1 randomized treatment and the end of Stage 1 run-in, and between the end of Stage 2 randomized treatment and the end of Stage 1 run-out. The study was completed and results have been published.

The Improving Asthma Control Trial (IMPACT) was a double-blind, randomized, parallel group design clinical study to determine the best long-term strategy for treating adults with mild asthma who experienced symptoms more than occasionally. The study tested whether these patients should be taking anti-inflammatory medications on a daily basis and whether a newer class of medications provided the same benefit as older drugs. In the IMPACT study, 225 adults with mild asthma, who had more than occasional symptoms, were enrolled in six clinical research centers. Following an initial evaluation, patients were randomized to receive either a twice daily inhaled corticosteroid, a twice daily anti-leukotriene, or a placebo. All patients received treatment for symptoms if, and when, they occured. The primary outcome was AM PEF. Other outcomes included FEV1 before and after bronchodilator treatment, the frequency of exacerbations, the degree of asthma control, the number of symptom-free days, and the quality of life. Recruitment ended in 2003. Study results were published in the April 14, 2005 issue of the New England Journal of Medicine. In April 2001 NHLBI initiated an ancillary study to IMPACT entitled "Modification of Allergic Immunologic Response by Leukotriene Antagonists" under R01HL67684. The ancillary study has its own site in this database.

The Smoking Modulates Outcomes of Glucocorticoid Therapy in Asthma (SMOG) study was a randomized, double-blind, cross-over study, which compared the effect of inhaled corticosteroid treatment delivered twice daily for 8 weeks in the following two groups of patients with persistent asthma: 1) smokers; and 2) non-smokers. Smokers and non-smokers were matched into pairs according to gender and FEV1 status prior to the run-in period. Each member of the matched pair was randomized together to the same crossover sequence. There were 96 patients ages 18 to 35. The primary outcome was change in pre-bronchodilator FEV1 over the 8-week treatment period in smokers compared with non-smokers. Secondary outcomes were AM and PM PEF, PC20 methacholine, and markers of inflammation in induced sputum. A secondary comparison examined the effect of 8 weeks of treatment with a leukotriene receptor antagonist in asthmatics who smoked to those who did not. An additional analysis compared the response to inhaled corticosteroid with the response to leukotriene receptor antagonist. The study was completed and results have been submitted to a journal for publication.

The Salmeterol and Leukotriene Modifiers versus ICS Treatment (SLIMSIT) study initiated recruitment in September 2002. The goal was to randomize 180 participants. SLIMSIT was a 36-week, double-blind, placebo-controlled, cross-over study, with time to treatment failure as the primary endpoint. Prior to each double-blind treatment phase, participants underwent a 4-week run-in period with combined inhaled beclomethasone HFA and the leukotriene receptor antagonist (LTRA) montelukast. This was followed by 14 weeks of double-blind treatment. During the initial 4-week run-in period, participants who met National Asthma Education Program criteria for moderate persistent asthma received a controller regimen to obtain baseline information on symptoms, beta-agonist use, and PEF for use in defining treatment failure for each participant over the duration of the study. The final visit of this run-in period served as the baseline of comparison for the study variables measured during the initial treatment phase. At the end of the initial run-in, participants with stable asthma symptoms were randomized to one of the following two treatment regimens for 14 weeks: 1) daily oral placebo, twice daily inhalation of salmeterol 50 mg by dry powder inhaler (DPI), and twice daily inhalation of beclomethasone HFA 80 mg by MDI; or 2) once daily oral montelukast 10 mg, twice daily inhalation of salmeterol 50 mg by DPI, and twice daily inhalation of placebo. Active beclomethasone HFA and the beclomethasone HFA placebo were given via a MDI delivery device, while salmeterol was given by a DPI Diskusâ. A computer interface randomized participants into the two treatment groups, stratifying by clinical center and FEV1 at the randomization visit (less than 80% versus greater than 80% of predicted FEV1). During the first treatment period, participants made three visits to the clinic over 14 weeks. These visits included re-assessment of the study variables and careful monitoring for increasing asthma symptoms and potential treatment failure. Subsequently, participants entered a second run-in period in which they received single-blind treatment with inhaled beclomethasone HFA and oral montelukast as in the first run-in period. At the end of the second run-in period, participants crossed over to the alternate treatment regimen for the second 14-week treatment phase, which included three visits to the clinic. These visits again included re-assessment of the study variables and careful monitoring for increasing asthma symptoms and potential treatment failure. DSMB recommended termination of the study prior to target enrollment because sufficient data about the primary outcome had been obtained. SLIMSIT results were presented at the May 2005 American Thoracic Society Annual Meeting. The data are under analysis for subsequent publication.

The Predicting Responses for Inhaled Corticosteroid Efficacy (PRICE) study was a follow-up study that looked for additional predictive biomarkers of response to inhaled corticosteroids. The study also evaluated whether short-term response to inhaled corticosteroids predicted asthma control and exacerbation rate, and whether it correlated with elastic recoil and upstream resistance. In this study, adults with a history of asthma underwent 6 weeks of ICS treatment, then were stratified by response and randomized in a double-blind fashion to continue ICS therapy or receive placebo for 16 weeks. ACRN investigators found that after 6 weeks of ICS therapy, patients with a good (15%) versus poor (less than 5%) increase in FEV1 experienced significantly better asthma control during continued ICS treatment. Interestingly, nitric oxide concentration in exhaled breath and airway sputum eosinophils, generally considered biomarkers of airway inflammation, were not significantly correlated with ICS treatment response. Explanation for this divergence in findings is unclear. PRICE results were presented at the May 2005 American Thoracic Society Annual Meeting

In the Genetics of Asthma in Latino Americans (GALA) study, two ACRN centers compared asthma-related clinical characteristics of 684 Mexican and Puerto Rican asthmatics recruited from San Francisco, New York City, Puerto Rico, and Mexico City. Results of the published study indicate that asthmatic Puerto Ricans had reduced lung function, greater morbidity, and longer asthma duration than asthmatic Mexicans.

The ACRN was renewed in September 2003 through July 2008. New protocols are under development and underway.

The Long Acting Beta Agonist Response by GEnotype (LARGE) study is the first protocol of ACRN II. It is a 60-week randomized, double-blind, cross-over study to compare the effects of long-acting beta-agonists in patients with asthma who are receiving inhaled corticosteroids and who express two distinct polymorphisms of the beta2-adrenergic receptor. The primary hypothesis is that those with the B16 Arg/Arg genotype will have worse asthma control, as defined by AM PEF rate, than those with the B16 Guj/Guj genotype. Recruitment started in December 2004 with a target of 80 randomized patients. See NCT00200967 for more information on this study.

Eligibility Criteria:
Patients with asthma; specific eligibility criteria vary for each study.